1. World Health Organization: Communicable Disease Surveillance and Response Containing. Antimicrobial Resistance: Review of the Literature and Report of a WHO Workshop on the Development of a Global Strategy for the Containment of Antimicrobial Resistance. Geneva, Switzerland. 1999
2. Centers for disease control and prevention, food and drug administration, national institutes of health: A Public Health Action Plan to Combat Antimicrobial Resistance. [ http://www.cdc.gov/drugresistance/actionplan/index.htm ]
3. Jones RN, Fritsche TR, Moet GJ: In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn®, Wyeth) formulation. Diagnostic Microbiology and Infectious Disease. 2008, 61: 76-79. 10.1016/j.diagmicrobio.2007.12.010.
4. Rodriguez CA, Zuluaga AF, Salazar BE, Agudelo M, Vesga O: Experimental comparison of 11 generic products (GP) of oxacillin (OXA) with the original compound (OC) in terms of concentration of active principle (CAP), in vitro activity, and in vivo efficacy, using the neutropenic murine thigh infection model (NMTIM). Abstr. A-1305. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D.C. 2004, 28-
5. Zuluaga AF, Salazar BE, Loaiza SA, Agudelo M, Vesga O: Therapeutic equivalence (TE) with the original compound (OC) of 8 genetic products (GP) of Ampicillin (AMP) determined in the neutropenic murine thigh infection model (NMTIM). Abstr. E- 203344th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, D.C. 2004